1 2 3 >  Last ›
November 30, 2021
American CryoStem Completes Clinical Protocol Design for Long COVID Study
EATONTOWN, NJ / ACCESSWIRE / November 30, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a leading clinical-stage biotechnology developer of adipose-derived stem cell therapies today announced completion of its Phase I clinical protocol design for the treatment of Long COVID. American CryoStem anticipates that the protocol will be filed as an FDA Phase I IND in cooperation with a major US medical center in Q-1, 2022.
November 23, 2021
American CryoStem Announces the Addition of John Schwartz, PhD to Its Advisory Board
EATONTOWN, NJ / ACCESSWIRE / November 23, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a leading clinical-stage biotechnology developer of adipose tissue-based cellular technologies for Regenerative and Personalized Medicine announced today that it has added John "Jay" Schwartz, PhD to its Scientific and Medical Advisory Board.
November 16, 2021
American CryoStem to Study New Standardized Treatment Protocols for Wound Healing
EATONTOWN, NJ / ACCESSWIRE / November 16, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has completed the development of a new standardized wound healing protocol utilizing its tissue based technologies with Advanced Regenerative Associates (Tinton Falls, NJ). The Company's wound healing technologies rely on exemptions from FDA clinical study and approval for the use of human tissue and cell products (PHS 361 and 21CFR1271.10) and is incorporated into the current standards of care protocols currently in use. The new protocol is focusing on realigning the microenvironment of the treatment area to achieve greater healing support during the treatment period utilizing current standard of care protocols. The initial rollout is fashioned as a study to collect additional information about the wound environment and healing progress. The Company intends to obtain informed consent from each participant for the collection, analysis and potential publication of the assessment data as required under current regulations.
November 12, 2021
American CryoStem Enters into an Agreement to Exchange Shares held by ACS Global, Inc
EATONTOWN, NJ / ACCESSWIRE / November 12, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a leading strategic cellular application developer, global licensor of patented adipose tissue-based technologies for the Regenerative and Personalized Medicine industries, today announced an agreement has been reached between the Company and ACS Global, Inc to exchange 20,000,000 million CRYO common shares currently held by ACS Global, Inc for 1,000,000 shares of preferred stock. Terms of the new preferred stock were not disclosed.
May 6, 2021
American CryoStem Executes LOI with Advanced Regenerative Associates to Conduct Wound Healing Clinical Study
EATONTOWN, NJ / ACCESSWIRE / May 6, 2021 / American CryoStem Corporation (OTC PINK:CRYO) a clinical-stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and therapies announced today, that it has signed a Letter of Intent (LOI) with Advanced Regenerative Associates, LLC ("ARA") of Tinton Falls, NJ for the development of a cell-based wound covering treatment for non-healing wounds, skin ulcers, and limb ischemia associated with type II diabetes, burns, and other systemic conditions.
March 11, 2021
American CryoStem Announces Patient Biomaterial Processing for its Post-Concussion Syndrome (PCS) Phase I Clinical Trial
EATONTOWN, NJ / ACCESSWIRE / March 11, 2021 / American CryoStem Corporation (OTC: CRYO) a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has begun processing patient's adipose tissue and culturing mesenchymal stem cells (ATCellâ„¢), for use in its FDA approved IND Phase I Clinical Trial.
February 25, 2021
American CryoStem and BioTherapeutic Labs Corp. Enter into R&D, Collaboration and Marketing Agreement
EATONTOWN, NJ / ACCESSWIRE / February 25, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies, announced today that it has entered into an Agreement with BioTherapeutic Labs Corp. (BTL) an FDA registered Umbilical Cord Tissue Manufacturing Company headquartered in Boca Raton, Florida.
January 6, 2021
American CryoStem Enters into a Cooperative Research and Development Agreement (CRADA) to Develop Standardized Treatment Protocols
EATONTOWN, NJ / ACCESSWIRE / January 6, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a clinical stage biotechnology Company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) authorized by published code 15 U.S.C. 3710a of US Title 15 Commerce and Trade. (https://www.disa.mil/about/cto/crada-process-overview) The Collaborative work will be conducted at the Biomedical Research Laboratory in Bethesda, Maryland.
 1 2 3 >  Last ›